EC
AKBA icon

EcoR1 Capital’s Akebia Therapeutics AKBA Stock Holding History

EcoR1 Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,425,000
Closed -$13.6M – 35
2018
Q1 		$13.6M Buy
+1,425,000
New +$19.9M 1.36% 18

Other funds holding AKBA

CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EcoR1 Capital's AKBA Position: Q2 2018 in Review

EcoR1 Capital sold out of Akebia Therapeutics (AKBA) in Q2 2018, closing a stake of 1,425,000 shares — an estimated $13.6M sold.

EcoR1 Capital first reported a position in AKBA in Q1 2018 and held it in 1 quarter. The position peaked at $13.6M in Q1 2018. 145 funds tracked by Wall St. Rank hold AKBA as of Q2 2018.

  • EcoR1 Capital reported no remaining Akebia Therapeutics position as of Q2 2018 after selling out during the quarter.
  • EcoR1 Capital sold 1,425,000 Akebia Therapeutics shares in Q2 2018, an estimated $13.6M.
  • EcoR1 Capital first reported a position in Akebia Therapeutics in Q1 2018 and held it in 1 quarter.
  • EcoR1 Capital's Akebia Therapeutics position peaked at $13.6M in Q1 2018.
  • 145 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2018.

Based on EcoR1 Capital's 13F filing for Q2 2018, filed 14 Aug 2018.